Search research articles
Contact Us
Filters
Showing results (71-80 of 185) with videos related to
Page
of 19
Sort By:
International Journal of Clinical Oncology
|
March 25, 2011
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma
Hiroshi Tsuruta, Takamitsu Inoue, Shintaro Narita, et al.
Progress in Transplantation (Aliso Viejo, Calif.)
|
December 10, 2014
De novo renal cell carcinoma in an allograft kidney treated with nephron-sparing surgery: a case report
Kazuyuki Numakura, Shigeru Satoh, Norihiko Tsuchiya, et al.
Urology
|
February 5, 2013
Laparoendoscopic single-site plus one trocar donor nephrectomy using the GelPort: initial clinical experience
Takamitsu Inoue, Norihiko Tsuchiya, Shintaro Narita, et al.
Clinical and Experimental Nephrology
|
September 8, 2019
Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study
Nobuhiro Fujiyama, Shigeru Satoh, Mitsuru Saito, et al.
British Journal of Clinical Pharmacology
|
April 24, 2008
Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients
Shigeru Satoh, Hideaki Kagaya, Mitsuru Saito, et al.
Cancer Letters
|
October 19, 2005
Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients
Takamitsu Inoue, Takuo Ito, Shintaro Narita, et al.
Pharmacogenomics
|
October 11, 2014
Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation
Shigeru Satoh, Takenori Niioka, Hideaki Kagaya, et al.
Oncotarget
|
January 18, 2018
Fatty acid binding protein 4 enhances prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production
Mingguo Huang, Shintaro Narita, Takamitsu Inoue, et al.
Japanese Journal of Clinical Oncology
|
April 9, 2011
A case of intratesticular endometrioid papillary cystadenocarcinoma
Kazuyuki Numakura, Norihiko Tsuchiya, Hiroshi Tsuruta, et al.
Transplantation
|
December 13, 2005
Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus
Kazuyuki Numakura, Shigeru Satoh, Norihiko Tsuchiya, et al.
Page
of 19
Search research articles
Search
Showing results (71-80 of 185) with videos related to
Sort By:
Page
of 19
International Journal of Clinical Oncology
|
March 25, 2011
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma
Hiroshi Tsuruta, Takamitsu Inoue, Shintaro Narita, et al.
Progress in Transplantation (Aliso Viejo, Calif.)
|
December 10, 2014
De novo renal cell carcinoma in an allograft kidney treated with nephron-sparing surgery: a case report
Kazuyuki Numakura, Shigeru Satoh, Norihiko Tsuchiya, et al.
Urology
|
February 5, 2013
Laparoendoscopic single-site plus one trocar donor nephrectomy using the GelPort: initial clinical experience
Takamitsu Inoue, Norihiko Tsuchiya, Shintaro Narita, et al.
Clinical and Experimental Nephrology
|
September 8, 2019
Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study
Nobuhiro Fujiyama, Shigeru Satoh, Mitsuru Saito, et al.
British Journal of Clinical Pharmacology
|
April 24, 2008
Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients
Shigeru Satoh, Hideaki Kagaya, Mitsuru Saito, et al.
Cancer Letters
|
October 19, 2005
Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients
Takamitsu Inoue, Takuo Ito, Shintaro Narita, et al.
Pharmacogenomics
|
October 11, 2014
Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation
Shigeru Satoh, Takenori Niioka, Hideaki Kagaya, et al.
Oncotarget
|
January 18, 2018
Fatty acid binding protein 4 enhances prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production
Mingguo Huang, Shintaro Narita, Takamitsu Inoue, et al.
Japanese Journal of Clinical Oncology
|
April 9, 2011
A case of intratesticular endometrioid papillary cystadenocarcinoma
Kazuyuki Numakura, Norihiko Tsuchiya, Hiroshi Tsuruta, et al.
Transplantation
|
December 13, 2005
Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus
Kazuyuki Numakura, Shigeru Satoh, Norihiko Tsuchiya, et al.
Page
of 19